Literature DB >> 15897303

Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.

C Röcken1, R Menard, F Bühling, S Vöckler, J Raynes, B Stix, S Krüger, A Roessner, T Kähne.   

Abstract

BACKGROUND: AA amyloidosis develops in patients with chronic inflammatory diseases. The AA amyloid proteins are proteolytic fragments obtained from serum amyloid A (SAA). Previous studies have provided evidence that endosomes or lysosomes might be involved in the processing of SAA, and contribute to the pathology of AA amyloidosis.
OBJECTIVE: To investigate the anatomical distribution of cathepsin (Cath) B and CathL in AA amyloidosis and their ability to process SAA and AA amyloid proteins.
METHODS: and results: CathB and CathL were found immunohistochemically in every patient with AA amyloidosis and displayed a spatial relationship with amyloid in all the cases studied. Both degraded SAA and AA amyloid proteins in vitro. With the help of mass spectrometry 27 fragments were identified after incubation of SAA with CathB, nine of which resembled AA amyloid proteins, and seven fragments after incubation with CathL. CathL did not generate AA amyloid-like peptides. When native human AA amyloid proteins were used as a substrate 26 fragments were identified after incubation with CathB and 18 after incubation with CathL.
CONCLUSION: The two most abundant and ubiquitously expressed lysosomal proteases can cleave SAA and AA amyloid proteins. CathB generates nine AA amyloid-like proteins by its carboxypeptidase activity, whereas CathL may prevent the formation of AA amyloid proteins by endoproteolytic activity within the N-terminal region of SAA. This is particularly interesting, because AA amyloidosis is a systemic disease affecting many organs and tissue types, almost all of which express CathB and CathL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897303      PMCID: PMC1755524          DOI: 10.1136/ard.2004.030429

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

Review 1.  Emerging roles for cysteine proteases in human biology.

Authors:  H A Chapman; R J Riese; G P Shi
Journal:  Annu Rev Physiol       Date:  1997       Impact factor: 19.318

2.  Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis.

Authors:  G T Westermark; P Westermark; K Sletten
Journal:  Lab Invest       Date:  1987-07       Impact factor: 5.662

3.  Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis.

Authors:  D Müller; A Roessner; C Röcken
Journal:  Virchows Arch       Date:  2000-11       Impact factor: 4.064

4.  Characterization of high molecular weight amyloid A proteins.

Authors:  F Prelli; M Pras; S Shtrasburg; B Frangione
Journal:  Scand J Immunol       Date:  1991-06       Impact factor: 3.487

5.  Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis.

Authors:  K Migita; K Eguchi; T Tsukada; Y Kawabe; H Takashima; M Mine; T Aoyagi; Y Ichinose; S Nagataki
Journal:  Lab Invest       Date:  1996-09       Impact factor: 5.662

6.  The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils.

Authors:  M Levin; E C Franklin; B Frangione; M Pras
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

7.  Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy.

Authors:  Elena Elimova; Robert Kisilevsky; Walter A Szarek; John B Ancsin
Journal:  FASEB J       Date:  2004-09-02       Impact factor: 5.191

8.  Identification of two novel amyloid A protein subsets coexisting in an individual patient of AA-amyloidosis.

Authors:  S Baba; T Takahashi; T Kasama; H Shirasawa
Journal:  Biochim Biophys Acta       Date:  1992-12-10

9.  Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A.

Authors:  T Yamada; J J Liepnieks; B Kluve-Beckerman; M D Benson
Journal:  Scand J Immunol       Date:  1995-01       Impact factor: 3.487

10.  In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation.

Authors:  T Yamada; B Kluve-Beckerman; J J Liepnieks; M D Benson
Journal:  Scand J Immunol       Date:  1995-06       Impact factor: 3.487

View more
  24 in total

1.  Cellular mechanism of fibril formation from serum amyloid A1 protein.

Authors:  Stephanie Claus; Katrin Meinhardt; Tobias Aumüller; Ioana Puscalau-Girtu; Julia Linder; Christian Haupt; Paul Walther; Tatiana Syrovets; Thomas Simmet; Marcus Fändrich
Journal:  EMBO Rep       Date:  2017-06-21       Impact factor: 8.807

2.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

3.  Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2016-10-15       Impact factor: 5.922

4.  Thermal transitions in serum amyloid A in solution and on the lipid: implications for structure and stability of acute-phase HDL.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

5.  High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation.

Authors:  Preetha Shridas; Maria C De Beer; Nancy R Webb
Journal:  J Biol Chem       Date:  2018-07-05       Impact factor: 5.157

6.  Serum amyloid A promotes LPS clearance and suppresses LPS-induced inflammation and tissue injury.

Authors:  Ni Cheng; Yurong Liang; Xiaoping Du; Richard D Ye
Journal:  EMBO Rep       Date:  2018-08-20       Impact factor: 8.807

7.  Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice.

Authors:  Thomas Wartmann; Julia Mayerle; Thilo Kähne; Miklós Sahin-Tóth; Manuel Ruthenbürger; Rainer Matthias; Anne Kruse; Thomas Reinheckel; Christoph Peters; F Ulrich Weiss; Matthias Sendler; Hans Lippert; Hans-Ulrich Schulz; Ali Aghdassi; Annegret Dummer; Steffen Teller; Walter Halangk; Markus M Lerch
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

8.  Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.

Authors:  S L Wood; M Rogers; D A Cairns; A Paul; D Thompson; N S Vasudev; P J Selby; R E Banks
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene.

Authors:  Magdalena Eriksson; Stefan Schönland; Saniye Yumlu; Ute Hegenbart; Hanna von Hutten; Zarina Gioeva; Peter Lohse; Janine Büttner; Hartmut Schmidt; Christoph Röcken
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

10.  A multiplexed analysis approach identifies new association of inflammatory proteins in patients with overactive bladder.

Authors:  Emily Ma; Joel Vetter; Laura Bliss; H Henry Lai; Indira U Mysorekar; Sanjay Jain
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.